This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond
by Aparajita Dutta
After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.
AZNPositive Net Change LLYNegative Net Change XLVNegative Net Change VHTNegative Net Change IXJNegative Net Change
etfs medical
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities
by Zacks Equity Research
PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.
BSXNegative Net Change CAHNegative Net Change IDXXPositive Net Change PACBNegative Net Change
medical medical-devices
SENS Stock Up as Eversense 365 Enters AID Market With twiist System
by Zacks Equity Research
Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.
BSXNegative Net Change ISRGPositive Net Change SENSPositive Net Change MEDPNegative Net Change
medical medical-devices
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
by Zacks Equity Research
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
AZNPositive Net Change JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Biotech ETFs Are Rallying Hard
by Sanghamitra Saha
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
IBBPositive Net Change SPYPositive Net Change XBIPositive Net Change IDNAPositive Net Change CANCPositive Net Change
etfs medical
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 MedTech Stocks That Crushed the S&P 500 Over the Past Year
by Indrajit Bandyopadhyay
TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.
CAHNegative Net Change TMDXNegative Net Change KRMDNegative Net Change
medical medical-devices
Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress
by Zacks Equity Research
Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.
JNJNegative Net Change BAYRYNegative Net Change FOLDNo Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure
BMYNegative Net Change PFEPositive Net Change MRKNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries?
by Indrajit Bandyopadhyay
ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.
JNJNegative Net Change MDTNegative Net Change ISRGPositive Net Change
medical medical-devices
Is it the Right Time to Add STERIS Stock to Your Portfolio?
by Zacks Equity Research
STE is buoyed by strong Healthcare and AST growth, solid margins and balance sheet strength, even as macro pressures and competition loom.
BSXNegative Net Change DGXNegative Net Change STENegative Net Change PAHCNegative Net Change
medical medical-devices
3 Medical Service Industry Stocks Set to Tackle Workforce Challenges
by Moumi Mondal
Medical services stocks like MEDP, EHAB and PGNY benefit from tech-driven care models even as staffing gaps pressure margins.
MEDPNegative Net Change PGNYNegative Net Change EHABNegative Net Change
medical
Do Options Traders Know Something About Avadel Pharmaceuticals Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Avadel Pharmaceuticals stock based on the movements in the options market lately.
AVDLPositive Net Change
medical
Tempus AI Stock Surges 82.4% in a Year: What's Driving It?
by Zacks Equity Research
TEM shares are up 82.4% in a year as Genomics revenues surge, Data & Services scale, FDA clearances and EBITDA turns positive.
DGXNegative Net Change CRLPositive Net Change PAHCNegative Net Change TEMNegative Net Change
medical
Here's What We Expect From AbbVie's Immunology Segment in Q4
by Sundeep Ganoria
ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Zacks Industry Outlook Highlights Tenet Healthcare, Universal Health Services and Community Health Systems
by Zacks Equity Research
Tenet Healthcare stands out as hospitals battle rising costs, care migration, and margin pressure across a strained industry.
UHSNegative Net Change THCNegative Net Change CYHNegative Net Change
medical
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies
by Zacks Equity Research
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
GSKPositive Net Change CRMDPositive Net Change IONSNegative Net Change KROSPositive Net Change
biotechs medical pharmaceuticals
CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois
by Zacks Equity Research
Centene expands its Medicaid strategy by partnering with Cityblock Health to serve 10,000 Illinois members with 24/7 wrap-around care.
RIGLNegative Net Change CNCNegative Net Change CRMDPositive Net Change EXASPositive Net Change
insurance medical
Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell?
by Debanjana Dey
HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.
TDOCNegative Net Change HIMSNegative Net Change DOCSPositive Net Change
medical medical-devices
INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite
by Zacks Equity Research
Inogen launches Aurora CPAP masks to expand its respiratory care suite and enter the growing sleep apnea market.
BSXNegative Net Change CAHNegative Net Change IDXXPositive Net Change INGNNegative Net Change
medical medical-devices
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.
FOLDNo Net Change CRMDPositive Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
The Zacks Analyst Blog Highlights Micron Technology, Roche and UnitedHealth
by Zacks Equity Research
Micron Technology, Roche and UnitedHealth highlight diverging opportunities across technology, pharmaceuticals and managed care.
RHHBYPositive Net Change UNHNegative Net Change MUPositive Net Change
computers medical pharmaceuticals
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
by Zacks Equity Research
Soleno Therapeutics leads a rebound in small drug stocks as innovation, pipeline progress and M&A activity fuel optimism for 2026.
IRWDPositive Net Change NKTRNegative Net Change RIGLNegative Net Change SLNONegative Net Change MRKRNegative Net Change
medical pharmaceuticals
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
by Ahan Chakraborty
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change VTYXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Hospital Industry Reshaping Under Strain: 3 Stocks Worth Watching
by Kaibalya Pravo Dey
THC, UHS and CYH are showing strength through outpatient focus and efficiency-improving efforts, despite hospital industry headwinds.
THCNegative Net Change UHSNegative Net Change CYHNegative Net Change
hospitals medical